Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-28
2006-02-28
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S252100, C544S336000, C546S188000, C546S191000
Reexamination Certificate
active
07005436
ABSTRACT:
Novel heterocyclo compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+current IKur), methods of using such compounds in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compositions containing such compounds.
REFERENCES:
patent: 3097209 (1963-07-01), Janssen
patent: 5612359 (1997-03-01), Murugesan
patent: 5631282 (1997-05-01), Goetz
patent: 5670504 (1997-09-01), Bochis et al.
patent: 5679705 (1997-10-01), Baker et al.
patent: 5696156 (1997-12-01), Baker et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: WO 00/01389 (2000-01-01), None
patent: WO 2003088908 (2003-10-01), None
Chandy and Gutman, “Voltage-gated potassium channel genes” in Handbook of Receptors and Channels—Ligand and Voltage-gated Ion Channels, ed. R.A. North, 1995.
Doupnik et al., Curr. Opin. Neurobiol. 5:268, 1995.
Chandy et al., J. Exp. Med. 160, 369, 1984.
Price et al., Proc. Natl, Acad, Sci. USA, 86, 10171, 1989.
Leonard et al., Proc. Natl. Acad. Sci, USA, 89, 10094, 1992.
Lin et al., J. exp. Med, 177, 637, 1993.
Singh B.N., Vaughan Williams E.M. “A Third Class of Anti-Arrhythmic Action: Effects On Atrial And Ventricular Intracellular Potentials And Other Pharmacological Actions On Cardiac Muscle, of MJ 1999 and AH 3747” Br. J. Pharmacol 1970; 39:675-689.
Singh B.N., Vaughan Williams E.M, “The Effect of Amiodarone, A New Anti-Anginal Drug, On Cardiac Muscle”, Br J. Pharmacol 1970; 39:657-667.
Decoursey et al., Nature, 307, 465, 1984.
Sanguinetti and Jurkiewicz, Two Components Of Cardiac Delayed Rectifier K+ Current: Differential Sensitivity To Block By Class III Antiarrhythmic Agents, J Gen Physiol 1990, 96:195-215.
Balser J.R. Bennett, P.B., Hondeghem, L.M. and Roden, D.M. Suppression Of Time-Dependent Outward Current In Guinea Pig Ventricular Myocytes: Actions Of Quinidine And Amiodarone. Circ. Res. 1991, 69:519-529.
Nademanee, K. “The Amiodarone Odessey” .J.Am. Coll. Cardiol.1992;20:1063-1065.
Roden, D.M. “Current Status of Class III Antiarrhythmic Drug Therapy”, Am J. Cardiol, 1993; 72:44B-49B.
Hondeghem, L.M. “Development of Class III Antiarrhythmic Agents”. J.Cadiovasc.Cardiol. 20 (Suppl.2):S17-S22 (1992).
Wang et al., 1993, Circ Res 73:1061-1076.
Fedida et al., 1993, Circ Res 73:210-216.
Snyders et al., 1993, J Gen Physiol 101:513-543.
Swanson et al., (1990), Neuron 4:929-939.
Vaughn Williams, E.M. “Classification Of Antiarrhythmic Drugs” In Symposium on Cardiac Arrhythmias, edited by: E. Sandoe, E. Flensted-Jensen, K. Olesen; Sweden, Astra, Sodertalje, pp449-472, 1970.
Br. J. Pharmacol. May 1995;115(2):267-74.
Grissmer S, et al., Mol Pharmacol Jun. 1994;45(6):1227-34.
Petersen KR, and Nerbonne JM, Pflugers Arch Feb. 1999;437(3):381-92.
Bowlby MR, and Levitan IB, J Neurophysiol Jun. 1995;73(6):2221-9.
Kalman K, et al., J Biol Chem Mar. 6, 1998;273(10):5851-7.
Cochran et al., “Regionally selective alterations in local cerebral glucose utilization evoked by charybdotoxin, a blocker of central voltage-activated K+−channels,” Eur J Neurosci. Nov. 2001;14(9):1455-63.
Coleman et al., “Subunit composition of Kv1 channels in human CNS,” J Neurochem. Aug. 1999;73(2):849-58.
Davies et al., “Kv channel subunit expression in rat pulmonary arteries,” Lung. 2001;179(3):147-61. Epub Feb. 4, 2002.
Frey et al., “Blocking of cloned and native delayed rectifier K channels from visceral smooth muscles by phencyclidine,” Neurogastroenterol Motil. Dec. 2000;12(6):509-16.
Hanson et al., “UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation,” British Journal of Pharmacology (1999), 126, 1707-1716.
Hatton et al., “Functional and molecular expression of a voltage-dependent K(+) channel (Kv1.1) in interstitial cells of Cajal,” J Physiol. Jun. 1, 2001 ;533 (Pt 2);315-27.
Koh et al., “Contribution of delayed rectifier potassium currents to the electrical activity of murine colonic smooth muscle,” J Physiol. Mar. 1, 1999; 515 (Pt 2):475-87.
Kourrich et al., “Kaliotoxin, a Kv1.1 and Kv1.3 channel blocker, improves associative learning in rats,” Behav Brain Res. Apr. 8, 2001;120(1):35-46.
Lopantsev et al., “Hyperexcitability of CA3 pyramidal cells in mice lacking the potassium channel subunit Kv1.1,” Epilepsia. Dec. 2003;44(12);1506-12.
MacDonald et al., “Members of the Kv1 and Kv2 voltage-dependent K(+) channel families regulate insulin secretion,” Mol Endocrinol. Aug. 2001;15(8):1423-35.
MacDonald et al., “Voltage-dependent K(+) channels in pancreatic beta cells: role, regulation and potential as therapeutic targets,” Diabetologia. Aug. 2003;46(8):1046-62. Epub Jun. 27, 2003.
Pozeg et al., “In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats,” Circulation. Apr. 22, 2003;107(15):2037-44. Epub Apr. 14, 2003.
Rho et al., “Developmental seizure susceptibility of kv1.1 potassium channel knockout mice,” Dev Neurosci. Nov. 1999;21(3-5):320-7.
Shah et al., “Immunosuppressive effects of a Kv1.3 inhibitor,” Cellular Immunology 221, (2003), 100-106.
Vianna-Jorge et al., “Shaker-type Kv1 channel blockers increase the peristaltic activity of guinea-pig ileum by stimulating actoylcholine and tachykinins release by the enteric nervous system,” Br J Pharmacol. Jan. 2003; 138(1):57-62.
Wickenden, “Potassium channels as anti-epileptic drug targets,” Neuropharmacology. Dec. 2002;43(7):1055-60.
Wulff et al., “Potassium channels as therapeutic targets for autoimmune disorders,” Current Opinion in Drug Discovery & Development 2003 6(5):640-647.
Xu et al., “The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity,” Proc Natl Acad Sci U S A. Mar. 2, 2004;101(9):3112-7. Epub Feb. 23, 2004 (epublished Feb. 23, 2004).
Beaudoin Serge
Finlay Heather
Gross Michael F.
Jeon Yoon T.
Lloyd John
Baxam Deanna L.
Bogie Terence J.
Bristol Myers Squibb Company
Desai Rita
Icagen Inc.
LandOfFree
Heterocyclo inhibitors of potassium channel function does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclo inhibitors of potassium channel function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclo inhibitors of potassium channel function will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3634608